Enhance MD vs Brello: Pricing, compounds, and verification
Compare Enhance MD vs Brello directly: Enhance MD advertises semaglutide from $49 and tirzepatide from $99 for the first month with flat-rate pricing; Brello’s pricing and offer details were not published or could not be verified. Early verdict: if low first-month price and explicit flat-rate at every dose matter, Enhance MD is clearly documented in the source, while Brello lacks verified public details.
See Enhance MD pricing and start
Key differences at a glance: Enhance MD vs Brello
The comparison below focuses on the most distinctive supported differences: introductory pricing and ongoing flat-rate policy, compound availability (semaglutide and tirzepatide), transparency and verification of published details, regulatory notes about compounded medications, and clinician-directed eligibility.
1. Introductory price and flat-rate approach
Enhance MD: Source shows semaglutide starting at $49 and tirzepatide starting at $99 for the first month, and states a flat-rate pricing model “the same price at every dose” with no fee escalation during titration. The source repeatedly describes the $49/$99 amounts as first-month introductory prices and notes ongoing flat-rate pricing is higher.
Brello: The captured landing-page evidence did not publish or verify current pricing details; the source states pricing, eligibility, pharmacy, state coverage and renewal terms may change and current details were not published or could not be verified.
Check Brello eligibility and live offer
2. Compound options available
Enhance MD: The source explicitly lists both compounded semaglutide and compounded tirzepatide offered on one platform and highlights that both are available for patients who want both active compound options.
Brello: The captured evidence did not verify which compounds or brands Brello offers; the source only captured a general statement that treatment is available when a licensed clinician determines it is medically appropriate and that medication-specific approval status must be confirmed.
3. Transparency and verification of details
Enhance MD: The source contains multiple pricing claims, details on flat-rate policy, and a stated patient volume of 10,000+ treated, all presented on the landing content captured for Enhance MD.
Brello: The captured affiliate landing page failed to load readable evidence; current details were not published or could not be verified according to the source. The source recommends confirming eligibility, medication, total cost, renewal terms and state availability before enrollment.
4. Regulatory and clinician-review notes
Both providers: The source recorded that treatment is available only when a licensed clinician determines it is medically appropriate. The Enhance MD source also includes a regulatory note that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The Brello capture similarly notes medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
Comparison table: Enhance MD vs Brello
| Criteria | Enhance MD | Brello |
|---|---|---|
| Starting price (semaglutide) | Semaglutide from $49 first month (source) | Not published or could not be verified (source) |
| Starting price (tirzepatide) | Tirzepatide from $99 first month (source) | Not published or could not be verified (source) |
| Ongoing pricing policy | Flat-rate: same price at every dose; no escalation during titration (source) | Not published or could not be verified; terms may change (source) |
| Compounds available | Both compounded semaglutide and tirzepatide available on one platform (source) | Not verified which compounds; medication-specific approval status must be confirmed (source) |
| Verification and transparency | Multiple published claims, captured landing-page evidence and 10,000+ patients treated (source) | Captured affiliate page failed to provide readable evidence; details not published or could not be verified (source) |
| Regulatory note | Compounded medications not FDA-approved and not reviewed by FDA (source) | Medication-specific approval status must be confirmed; branded and compounded products not interchangeable (source) |
How the differences affect a decision
If an explicit low first-month price and predictable flat-rate dosing are priorities, the captured Enhance MD information documents semaglutide from $49 and tirzepatide from $99 first-month offers and a flat-rate approach. If you need live-confirmed pricing, compound choice, renewal terms, pharmacy or state availability, the source for Brello was not verified and recommends confirming those items before enrollment.
View Enhance MD details and clinician review
Safety, clinician review, and compounded status
Both entries emphasize clinician-directed treatment. Enhance MD explicitly warns that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The Brello capture advises confirming medication-specific approval status and does not provide additional published evidence in the captured page.
Start Enhance MD intake and learn about testing
Conclusion: Enhance MD vs Brello
Enhance MD vs Brello: based on the captured sources, Enhance MD documents low first-month pricing (semaglutide from $49, tirzepatide from $99), a flat-rate pricing promise at every dose, and dual-compound availability with clinician review; Brello’s specific pricing, compounds, and terms were not published or could not be verified in the captured evidence. Verify clinician eligibility and medication approval for either provider as stated in the sources.
Choose Enhance MD if you prioritize documented low first-month prices, flat-rate dosing transparency, and on-platform access to both compounded semaglutide and tirzepatide.